A group of Israeli scientists argues that the medicine used to treat HIV has a direct impact on coronavirus, contributing to the recovery of patients in just a few days.
Israeli Russian-speaking Edition “Details” writes that Code Pharma has recently completed the first phase of the test of its Codivir drug for use against coronavirus. According to the general director of the company Cion Aney, the goal is to complete the tests for about three to six months, and then apply for an emergency permit for the use of the drug.
In the first phase of the tests held in the hospital in São Paulo (Brazil), 12 patients aged 18 to 60 years old with a COVID-19 of light and medium severity took part. Patients received two injections of the drug per day for 10 days. According to Maayan, in five patients during treatment there was a very strong decrease in the viral load. Codivir significantly suppressed the replication of the virus in all patients, the effect was noticeable three days after the start of treatment. Ayney notes that patients did not have significant side effects from the very treatment. In addition, those who received the drug did not have complications that very often appear at COVID-19.
Before the tests in Brazil Code Pharma informally tested the drug on patients in the Congo. “One hospital there began to introduce it to patients with COVID-19, and they fully recovered,” Aney says.
Laboratory tests also showed good results.